Bacloffen (Lioresal) in the long-term management of spasticity.
This report summarizes experience with baclofen (Lioresal) in the management of spasticity and muscle spasms in 113 patients treated for up to six years. Baclofen was found to be of little help in nine patients with spasticity of cerebral origin, but was effective in reducing spasticity of spinal origin in 72 out of 90 patients (80%). It also reduced the number and severity of spasms in 76 out of 87 patients (87%). Side effects necessitating reduction of dosage were experienced by 20% of patients. Baclofen appears to be a safe and effective agent in the management of spasticity, with the advantage that adequate dosage can usually be achieved without sedation. Beneficial effects have persisted throughout the follow-up period.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000627:therapeutic use*; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000150:complications; D002648:Child; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010264:Paraplegia / Q000150:complications; D011782:Quadriplegia / Q000150:complications; D013035:Spasm / Q000188:drug therapy* / Q000209:etiology
D000613:Aminobutyrates; D001418:Baclofen